NR1I2 and ovarian cancer: LXR [283–285], PXR [286], VDR [287–296] or CAR [297, 298] activation was shown to exert protective features against ovarian cancer, similar to BA-elicited effects suggesting that BAs may have a more profound role in protecting against ovarian cancer.